Single, Double, Triple: How the GLP-1 Research Peptides Differ

The short version: Semaglutide, Tirzepatide and Retatrutide are the three GLP-1 research peptides most often compared in the metabolic-research literature. The cleanest way to tell them apart isn’t the name — it’s how many receptors each one is built to activate. One. Two. Three. (And no, a 30 mg vial isn’t “stronger” than a 15 mg one — more on that below.)

What a “GLP-1 agonist” actually means

GLP-1, short for glucagon-like peptide-1, is a small signalling peptide the body produces. In the research literature it’s studied as one node in the wider system of metabolic signalling, and its role is to bind a specific receptor and switch it on.

That’s where the word agonist comes from. Picture the receptor as a lock and the peptide as a key cut to fit it: an agonist is a molecule shaped to turn that lock. A “GLP-1 receptor agonist” is simply a compound designed to activate the GLP-1 receptor, which is why researchers use these molecules as tools to study that pathway directly.

A quick primer on the receptors

GLP-1 and GIP (glucose-dependent insulinotropic polypeptide) belong to a family called incretins — signalling peptides studied for their part in metabolic signalling. Their receptors, together with the glucagon receptor, are class B G-protein-coupled receptors, or GPCRs: cell-surface proteins that pass a signal from outside the cell to the inside when the right molecule binds. The compounds in this article are agonists at one or more of those GPCRs.

Two pharmacology terms are worth knowing, because they come up constantly when these are compared. Affinity is how tightly a molecule binds its receptor. Potency is how much of the molecule it takes to produce a given level of receptor activation. Both are intrinsic properties of the molecule — a point that matters later when we get to vial sizes.

It’s also why many of these research peptides are structurally engineered. Modifications such as added fatty-acid chains are described in the literature as ways to slow how quickly the peptide is broken down, which makes the molecule more practical to work with. The newer compounds took a second step: rather than activating just one receptor, they were designed to fit more than one.

Semaglutide — the single agonist

Semaglutide is built to activate one receptor: GLP-1. It’s the most-studied of the three and the reference point the others are measured against. In research models it’s the single-pathway baseline — the compound you compare the others to when you want to see what adding a second or third receptor changes.

Tirzepatide — the dual agonist

Tirzepatide is designed to activate two receptors: GLP-1 and GIP. GIP is a second incretin receptor studied alongside GLP-1 in metabolic research. The question researchers look at is whether engaging two related pathways together behaves differently from engaging one on its own. That’s why Tirzepatide appears in the literature as a “dual” agonist, sometimes called a “twincretin.”

Retatrutide — the triple agonist

Retatrutide goes one step further, with three receptor targets: GLP-1, GIP, and the glucagon receptor. Adding that third receptor is what makes it the newest and most closely watched of the group in current research — it’s the furthest the “activate more than one receptor” idea has been taken so far. As with the others, the open question researchers study is what that extra target contributes.

Think of it as a panel with one, two, or three switches. Semaglutide flips one. Tirzepatide flips two. Retatrutide flips all three.

Side by side

Compound	Receptors targeted	Studied as
Semaglutide	GLP-1	Single agonist — the baseline
Tirzepatide	GLP-1 + GIP	Dual agonist (“twincretin”)
Retatrutide	GLP-1 + GIP + Glucagon	Triple agonist — newest

Why a 30 mg vial isn’t “stronger” than a 15 mg vial

This is one of the most common mix-ups we see, so it’s worth clearing up properly. People assume a 30 mg vial of a compound is “stronger” than a 15 mg vial of the same compound. It isn’t. The milligram figure on the label is the total amount of peptide in the vial — a quantity, not a measure of how powerful the molecule is.

It helps to separate three ideas that the single word “strength” tends to blur together:

Amount is the number on the label: how much total peptide is in the glass. A 30 mg vial simply holds twice the material of a 15 mg vial of the same compound.

Potency is a fixed property of the molecule itself — how tightly it binds its receptor and how strongly it activates it. A molecule of Retatrutide behaves like a molecule of Retatrutide whether it came from a 15 mg vial or a 30 mg one. The vial size doesn’t change the chemistry.

Concentration is a third, separate thing, and it’s set in the lab, not at the factory. These peptides ship as a lyophilised (freeze-dried) powder and are reconstituted with a chosen volume of solvent. The amount of solvent added is what determines the concentration of the working solution — so the very same 30 mg vial can be prepared more dilute or more concentrated depending only on how it’s reconstituted.

An everyday way to picture it: think of coffee. The size of the bag is the amount (the milligrams in the vial). How strong the coffee tastes in the cup is the concentration (set by how much water you add). And the variety of bean is the potency — fixed, no matter how big the bag is. Three different things, one misleading word.

So when you’re choosing between a 15 mg and a 30 mg option of the same peptide, you’re deciding how much total material you want on hand — not buying a weaker or a stronger product.

Why researchers line them up together

Because they form a clean progression. Hold one variable — the number of receptors activated — and step it from one to two to three, and you have exactly the kind of controlled comparison metabolic research is built on. Studying the three together is how you isolate what each additional receptor adds, rather than inferring it from a single compound on its own.

What actually decides your data: purity

With any of these peptides, a result is only as reliable as the vial behind it. If the identity is wrong or the purity is low, everything measured downstream is compromised — you’re no longer studying the compound you think you are. Every batch from JP Research is independently third-party tested for identity and >99% purity, with the Certificate of Analysis available to view before you order. Search it by compound name.

If you’re sourcing Semaglutide, Tirzepatide, Retatrutide or related compounds for research, you can browse the full catalogue and request a quote in seconds — no account, no checkout.

All products are supplied strictly for laboratory and research purposes only. Not for human or animal consumption.